Market Overview

A Peek Into The Market Before The Trading Starts

Related TSLA
Tesla Shares Have Hurdles To Clear In Order To Really Start Motoring
What Options Traders Are Watching This Week
Buffett and Musk: More Alike Than You'd Think (Fox Business)
Related TYC
Benzinga's Top Upgrades
Argus Research Upgrades Tyco International To Buy
Medtronic to Buy Covidien for $42.0 Billion (Fox Business)

Pre-open movers US stock futures declined in early pre-market trade, ahead of consumer sentiment data. The Reuter's/University of Michigan's consumer sentiment index is due at 9:55 a.m. ET. Futures for the Dow Jones Industrial Average dipped 37 points to 15,447.00, while the Standard & Poor's 500 index futures tumbled 5 points to 1,679.00. Futures for the Nasdaq 100 index fell 7.25 points to 3,042.75.

A Peek Into Global Markets European markets were mixed today, with the Spanish Ibex Index surging 1.06%, London's FTSE 100 index dropping 0.17% and STOXX Europe 600 Index falling 0.01%. German DAX 30 index fell 0.56% and French CAC 40 Index gained 0.64%. Spanish 10-year government bond yields increased 1 basis point to 4.65%.

Asian markets ended mostly lower today. Japan's core consumer price index increased 0.4% y/y in June, versus economists' expectations for a 0.3% rise. China's Shanghai Composite dropped 0.51%, while Japan's Nikkei Stock Average fell 2.97%. Australia's ASX/S&P500 gained 0.11%, India's Sensex tumbled 0.29% and Hong Kong's Heng Seng Index rose 0.31%.

Broker Recommendation Analysts at Deutsche Bank upgraded Tesla Motors (NASDAQ: TSLA) from “hold” to “buy.” The target price for Tesla Motors has been raised from $50 to $160.

Tesla's shares gained 5.36% to $130.72 in pre-market trading.

Breaking news

  • Tyco International (NYSE: TYC) reported a 45% drop in its fiscal third-quarter earnings. Tyco's quarterly profit fell to $135 million, or $0.28 per share, from $246 million, or $0.52 per share, in the year-ago period. To read the full news, click here.
  • Forest Laboratories (NYSE: FRX) and Pierre Fabre Laboratories announced today that FETZIMA, a once-daily serotonin and norepinephrine reuptake inhibitor (SNRI), discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories was approved by the U.S. FDA for the treatment of Major Depressive Disorder in adults. To read the full news, click here.
  • Stanley Black & Decker (NYSE: SWK) reported better-than-expected second-quarter earnings. Stanley Black & Decker's quarterly earnings rose to $187.1 million, or $1.23 per share, from $154.8 million, or $0.75 per share, in the year-earlier period. To read the full news, click here.
  • Newell Rubbermaid (NYSE: NWL) reported a better-than-expected second-quarter profit and lifted the low end of its earnings forecast for the year. Newell now projects adjusted earnings of $1.80 to $1.84 per share, versus its earlier outlook of $1.78 to $1.84 per share. To read the full news, click here.

Posted-In: Deutsche Bank US Stock FuturesNews Futures Global Pre-Market Outlook Markets


Related Articles (FRX + NWL)

Around the Web, We're Loving...

Get Benzinga's Newsletters